Optimi Health Corp.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Dane Stevens
- Full Time Employees
- 9
- Sector
- Process industries
- Industry
- Agricultural commodities/Milling
- Address
- 269 David Brown Way Squamish BC Canada V0X 1W0
- IPO Date
- Feb 25, 2021
- Website
- optimihealth.ca
- Similar Companies
- Business
- Optimi Health Corp. is a Canadian pharmaceutical manufacturer specializing in psychedelic medicines, including GMP-certified, naturally-derived MDMA and psilocybin products. The company produces and supplies pharmaceutical-grade psychedelic substances such as MDMA capsules in 40mg and 60mg dosages, natural psilocybin capsules of 5mg, alongside other psychedelic substances and functional mushrooms for health and wellness markets. Its product portfolio includes raw mushroom biomass, mushroom extracts, and various mushroom supplements derived from botanical sources, with fungi varieties including Lion's Mane, Chaga, Reishi, Turkey Tail, and Cordyceps. Optimi operates from two GMP-compliant, 10,000-square-foot manufacturing facilities located in British Columbia, Canada. The company targets regulated pharmaceutical markets and supplies active pharmaceutical ingredients and finished dosage forms to healthcare providers, primarily serving mental health treatment sectors in Canada and Australia. Founded in 2018 and headquartered in Vancouver, British Columbia, Optimi Health holds a Health Canada-issued Drug Establishment License and Controlled Drugs and Substances Dealer's License, qualifying it as a licensed pharmaceutical producer of psychedelic medicines in Canada. Recent major developments include the commercial launch of its 5mg natural psilocybin capsules for prescription use under Australia's Authorized Prescriber Scheme, complementing its existing 40mg and 60mg MDMA capsules distribution in Australia initiated in 2024. In 2025, Optimi expanded its production capacity with a forecast to supply MDMA capsules for over 5,000 patients globally and achieved multiple strategic partnerships, including supply agreements with Mind Medicine Australia and inclusion of its psilocybin capsules in Medibank's AUD 10 million insurance-backed psychotherapy program for Treatment-Resistant Depression. Additionally, Optimi signed a Letter of Intent with ATMA Journey Centers to advance Phase II clinical trials for Major Depressive Disorder therapies. The company has also completed significant international exports and shipments of GMP-certified MDMA and psilocybin capsules for PTSD and other mental health treatments, securing a leading position in the regulated psychedelic pharmaceutical sector. Optimi Health operates primarily within the psychedelics pharmaceutical industry and health and wellness segments, serving clinical and therapeutic applications in Canada, Australia, and expanding markets internationally. Its customer base includes healthcare providers, research institutions, and clinics focused on mental health therapies, particularly for conditions such as PTSD and Treatment-Resistant Depression. The company remains publicly listed on the Canadian Securities Exchange (CSE: OPTI), OTCQX (OPTHF), and Frankfurt Stock Exchange (FSE: 8BN), continuing to pursue growth through innovative product development, regulatory approvals, and strategic market expansions.
Company News
Optimi Health Completes MDMA Production for Phase 3 PTSD Trial in Canada, MAPS Trial in Israel and Commercial Supply in Australia
Optimi Health to Present at the ThinkEquity Conference
Optimi Health Appoints Melanie Pump to Board of Directors
Optimi Health Corp. (NASDAQ:OPTH) Stock Short Interest Jumps 109.1%
Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply
Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer
Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder
Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder
Optimi Health to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Optimi Health Establishes Discretionary Equity Facility
Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research
Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia